Plus therapeutics secures private placement of approximately $15 million in gross proceeds

Houston, march 04, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced the pricing of a private placement with gross proceeds to the company expected to be approximately $15.0 million. “this financing coupled with ongoing grant support strengthens our ability to rapidly advance our cns cancer therapies,” said marc h.
pstv Ratings Summary
pstv Quant Ranking